Arlette-28 is primarily used to provide long-term contraception, which is a therapeutic goal in family planning and reproductive control. This therapeutic benefit is applied continuously in women of childbearing age, and assists with maintaining functional stability by contributing to easing the overall symptom load related to reproductive risk. The primary use involves preventing pregnancy, managing hormonal sensitivities requiring estrogen avoidance, and supporting contraceptive needs during lactation or the postpartum period.

This medication is commonly used in clinical scenarios where the patient’s underlying health requires them to avoid estrogen, a key benefit that provides a relevant oral contraceptive option. For women with this need, it offers supportive therapeutic benefit and helps address the symptom cluster of reproductive risk during a sensitive period. Beyond its main function, Arlette-28 may also assist with managing certain symptoms related to the menstrual cycle, such as heavy bleeding (menorrhagia) or pronounced pain (dysmenorrhea), offering symptomatic relief that may assist with day-to-day comfort.

Quick Fact: Supportive Management for Menstrual Symptoms The medication may be part of symptomatic management for conditions characterized by increased discomfort, and may help patients cope more steadily with symptom fluctuations.

Official Eligibility Profile: Arlette-28

Arlette-28, a combined hormonal contraceptive, is intended for use by females of reproductive potential who do not have documented contraindications. The eligibility profile is strictly defined by factors that increase the risk of serious side effects, primarily blood clots (thromboembolism) and hormone-sensitive cancers.

Populations for whom use is Contraindicated (Must Not Use):

The use of this medication is absolutely prohibited in individuals with the following official regulatory exclusions:

• Age and Smoking: Females over 35 years of age who smoke (due to significantly increased cardiovascular risk).
• Blood Clot History: Current or history of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or heart attack.
• Hormone-Sensitive Cancers: Known or suspected breast cancer or other sex steroid-sensitive malignancies.
• Liver Disease: Current liver tumors (benign or malignant) or severe liver disease until liver function has fully normalized.
• Migraine with Aura: History of migraine headaches with focal neurological symptoms (aura) at any age.
• Postpartum: Non-breastfeeding women less than 21 days postpartum (or less than 42 days with other VTE risk factors).

Eligibility-Related Restrictions:

• Surgery/Immobilization: The medicine must be stopped at least four weeks before major surgery or during prolonged periods of immobility due to the increased VTE risk.
• Age: The medicine is not indicated for use in children before menarche or in the geriatric population. Use in women 40 years old is permitted only in the absence of other risk factors.

Interactions with other medicines and products

Official regulatory documents describe two primary categories of drug interactions that require close attention: those affecting the contraceptive efficacy of Arlette-28 and those involving safety constraints with certain co-administered medications.

Drugs that induce Cytochrome P450 enzymes (e.g., certain anti-seizure medicines, some anti-infectives, and St. John's Wort) may reduce the effectiveness of Arlette-28. This occurs by increasing the clearance of the hormonal components (levonorgestrel and ethinyl estradiol), which can lead to a risk of unintended pregnancy. Patients using these enzyme-inducing medications are generally advised to use an alternative, non-hormonal method of contraception during co-administration and for 28 days following their discontinuation.

Contraindicated Combinations

Arlette-28 is restricted from use concomitantly with specific Hepatitis C combination drug regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This restriction is mandated due to the potential for significant increases in liver enzymes (ALT).

Impact on Other Medicines

Arlette-28 may affect the therapeutic action of other medicines. For instance, it is documented to reduce the plasma concentrations of the anti-seizure medicine Lamotrigine, which may diminish its efficacy. Furthermore, Arlette-28 can increase the need for replacement doses of certain hormones, such as thyroid hormone or cortisol, due to changes in plasma protein binding globulins.

Arlette-28 contains desogestrel, a synthetic progestogen that functions primarily through its active metabolite, etonogestrel. Etonogestrel acts as a selective agonist at the progesterone receptor (PR), located within target cells, including those in the hypothalamus, pituitary gland, cervix, and endometrium.

Binding to the PR modulates gene transcription in the hypothalamic-pituitary-ovarian (HPO) axis. This action leads to the suppression of gonadotropin release, specifically inhibiting the pre-ovulatory Luteinizing Hormone (LH) surge from the anterior pituitary. The resultant low LH levels prevent follicular rupture and the release of an oocyte, a systemic effect termed anovulation.

Additionally, desogestrel modulates local cervical tissues. It induces physiochemical changes in the cervical mucus, increasing its viscosity and reducing its penetrability, which impairs sperm transit through the cervix. In the endometrium, the drug promotes stromal pseudodecidualization and glandular atrophy, leading to cellular and morphological alterations that modify the inner lining of the uterus.

How to Use Arlette-28: Administration Principles

Arlette-28 is a progestogen-only contraceptive administered by the oral route as a film-coated tablet. The usage pattern follows a continuous regimen to maintain a consistent concentration of the active ingredient, desogestrel.

Standard Dosing and Frequency

The regimen involves taking one tablet daily, which contains a dose of 0.075 mg of Desogestrel. This dose applies for the medication’s intended use. The medicine is taken at approximately the same time each day, aiming for a 24-hour interval between doses to maintain efficacy. Tablet intake is not dependent on meals and can be taken with or without food.

Continuous Use Protocol

The administration schedule is continuous: each pack contains 28 active tablets, and upon finishing one pack, the next one is started immediately on the following day, resulting in no hormone-free break. The medicine is designed for long-term use as a method of contraception.

Standard Protocol for Missed Doses

Adherence to the fixed timing is important. If a dose is missed by less than 12 hours from the scheduled time, the tablet is taken immediately. If the delay is more than 12 hours, the missed tablet is taken immediately and a non-hormonal barrier method of contraception (e.g., condoms) is used for the subsequent seven days. This protocol is necessary to re-establish intended usage conditions.

Research evidence / Overview of studies for Arlette-28

Evidence for use in Contraception and Pregnancy Prevention

Clinical research into the use of Arlette-28 for contraception was studied for its effectiveness primarily through Randomized Controlled Trials (RCTs) and systematic reviews. The focus was to examine measures of contraceptive efficacy, tracked using the Pearl Index, and explored outcomes related to ovulation inhibition. Systematic reviews describe patterns observed when measuring contraceptive efficacy in the observed populations under trial conditions. Comparative evidence is lacking to definitively rank Desogestrel against all other Progestogen-Only Pills (POPs) in modern trials, and evidence quality varies across studies, particularly older ones.

Evidence for Supportive Use in Menstrual Symptom Management

Research has also explored the medication's application in settings where women present with cycles of stability and flare-ups related to the menstrual cycle. This was primarily applied in studies examining patient-reported experiences where changes to the menstrual cycle and related outcomes related to physical discomfort were tracked as secondary measures. Studies monitored how symptoms evolved (like heavy bleeding or pain). The existing evidence is limited as the research focuses on documenting bleeding patterns rather than using symptomatic relief as a dedicated primary outcome, meaning certainty remains low for this specific application.

Evidence in Special Populations and Research Uncertainty

Research has been studied for its use in specific populations for whom the estrogen-free composition is relevant, such as nursing mothers (postpartum) and women with medical reasons to avoid estrogen. Available data show patterns related to contraceptive use in these groups. However, follow-up durations were limited in some trials, meaning data for certain groups remain insufficient. The overall body of evidence highlights what is known — and what is still uncertain. There is limited information for long-term outcomes extending beyond a single year of continuous administration, and research is ongoing in this area.

Common questions about Arlette-28 (FAQ)

Q: Can Arlette-28 interact with antibiotics?

A: Official product information notes that interactions can occur with certain anti-infectives that are known to induce liver enzymes. This process can increase the clearance of the hormonal component in Arlette-28, which may reduce its overall effectiveness. Regulatory documents typically state that an additional barrier method of contraception may be necessary during use of enzyme-inducing medicines and for 28 days after stopping them.

Q: Can I take Arlette-28 while breastfeeding my baby?

A: Studies and official information indicate that progestogen-only contraceptives, due to their composition, may be considered for use in breastfeeding women. While the active ingredient does pass into breast milk in small amounts, available data suggest this is not usually a cause for concern regarding infant growth or development. Determining individual suitability and risks is a medical decision.

Q: What should I do with expired or unused Arlette-28?

A: Government guidelines for drug disposal recommend using community drug take-back or mail-back programs when available. The product should not be disposed of by flushing or placing it directly in household trash. If a take-back program is unavailable, official recommendations describe an at-home disposal process that involves mixing the medicine with an undesirable substance and sealing it before placing it in the trash.

Q: How long does it take for Arlette-28 to become effective as birth control?

A: Official regulatory documents indicate that using a barrier method of contraception, such as a condom, for the first seven days of the first cycle may be necessary when initiating treatment. This measure is intended to ensure effective protection against pregnancy is established.

Q: What is the recommended age range for taking Arlette-28?

A: According to official labeling, Arlette-28 is not indicated for use in children before they have started menstruation (menarche). Use in women 40 years of age and older is permitted, provided they do not have other risk factors that might increase the chance of serious side effects.

Arlette-28 (Desogestrel/Ethinyl Estradiol) must be stored under specific conditions to maintain the stability and effectiveness of the hormonal components, as required by regulatory labeling.

Storage Conditions

Disposal Instructions

Expired or unused Arlette-28 must be disposed of according to local pharmaceutical waste requirements to prevent environmental release of hormones. The product should not be flushed down a toilet or placed in household trash unless a local regulation specifically states otherwise. Use a drug take-back location or mail-back program when available, as this is the preferred regulatory method for disposal.